Figure 3
In vivo transglycation activity of hydralazine.
Male BALB/c mice were injected with 50 mg/kg body weight of STZ for five consecutive days to induce diabetes. The induction of diabetes was confirmed after 30 days by measuring the blood glucose levels and HbA1c. Animals having blood glucose level of above 6.12 ± 1.7 mmol/L with ≥7.0 HbA1C were treated with either hydralazine (300 mg/L) or aminoguanidine (2.4 g/L). (A) Bar graph depicting the HbA1c of control mice, diabetic mice and diabetic mice treated with hydralazine or aminoguanidine at 30th, 45th, 60th and 90th day of experiment. Hydralazine decreased the HbA1c by 45th day (15 days of drug treatment) and was almost equal to that of control mice. The values represent mean ± SE, n = 6, P- value < 0.05. (B) Bar graph depicting the plasma fructosamine levels of control mice, diabetic mice and diabetic mice treated with hydralazine or aminoguanidine at 90th day of experiment. Fructosamine level was measured by using the NBT assay. The reduction of NBT to formazon was measured at 540 nm and levels were calculated using the standard fructosamine. Fructosamine levels were decreased with hydralazine treatment (The values represent mean ± SE, n = 6, P- value < 0.05).
